Navigation Links
Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results

XIANYANG, China, Nov. 12 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced financial results the third quarter ended September 30, 2009.


    Third Quarter 2009 Results
                             Q3 2009           Q3 2008            CHANGE
    Net Sales             $15.6 million     $7.5 million          +106.3%
    Gross Profit          $12.0 million     $3.8 million          +216.3%
    Net Income             $3.1 million     $0.6 million          +459.2%
    EPS (Fully Diluted)           $0.13            $0.02          +550.0%

    Nine Month 2009 Results
                          First 9M 2009     First 9M 2008         CHANGE
    Net Sales             $36.2 million     $23.8 million          +52.5%
    Gross Profit          $26.5 million     $13.3 million          +98.5%
    Net Income             $8.8 million      $4.1 million         +112.9%
    EPS (Fully Diluted)           $0.37             $0.18         +105.6%

Third Quarter 2009 Financial Results

Revenue for the third quarter of 2009 increased 106.3% to approximately $15.6 million compared to $7.5 million for the third quarter of 2008. The increase in revenue was primarily due to Biostar's flagship product, Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing") which accounted for 76.9% of the Company's revenues during the quarter. For the third quarter of 2009, the sales of Xin Aoxing increased 200.6% to $12.0 million with a gross margin of 84.1%, compared to $4.0 million in the third quarter of 2008. The increase was driven by Xin Aoxing penetrating a new province through local wholesalers in the third quarter of 2009 in addition to initiating sales in two provinces in the second quarter of 2008 CASH FLOWS FROM OPERATING ACTIVITIES Net income $8,810,355 $4,138,279 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization 470,833 485,051 Provision for doubtful accounts -- 186,085 Loss on disposal of building 248,730 -- Changes in operating assets and liabilities: Accounts receivable (6,118,030) (6,101,916) Inventories (389,966) (111,725) Deposit -- (285,676) Prepaid expenses and other receivables (1,505,755) 27,210 Accounts payable and accrued expenses 241,181 1,132,285 Customer and other deposits 63,363 (18,942) VAT tax payable 472,244 134,787 Income tax payable 574,387 (128,161) Net cash provided by (used in) operating activities 2,867,342 (542,723) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (9,897) (51,400) Deposit for acquisition of land use right (1,169,529) -- Net cash provided by (used in) Investing activities (1,179,426) (51,400) CASH FLOWS FROM FINANCING ACTIVITIES Repayment of short-term bank loan -- (554,508) Net cash provided by (used in) financing activities -- (554,508) Effect of exchange rate changes on cash and cash equivalents 2,435 105,262 Net Increase (Decrease) in cash and cash equivalents 1,690,351 (1,043,369) Cash and cash equivalents, beginning balance 758,316 2,286,419 Cash and cash equivalents, ending balance $2,448,667 $1,243,050 SUPPLEMENTAL DISCLOSURES: Interest payments $-- $39,807 Income tax payments $1,360,011 $747,217 SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Consummation of disposal of building $2,555,510 $-- For further information, contact: Ms. Elaine Zhao, CFO Tel: +1-626-456-2789 Email: John Mattio HC International, Inc. Tel: +1-914-669-5340 Email: Web:

SOURCE Biostar Pharmaceuticals, Inc.

2009. Biostar's focus on growing its rural distribution network also contributed to revenue growth in the third quarter. Up to September 2009, Biostar more than doubled its rural network retail locations to 3,500 outlets from 1,300 reported in the second quarter of 2009. Another Biostar's state approved drug, Tianqin Dysmenorrhea Capsule, contributed $1.1 million in revenue in the third quarter, an increase of 17.3% compared to $0.9 million in the third quarter of 2008.

Cost of goods sold for the three months ended September 30, 2009 was approximately $3.6 million or 23.0% of revenues as compared to $3.8 million or 49.8% of revenues for the three months ended September 30, 2008, Gross profits for the quarter were $12.0 million with gross margins of 77.0%, compared to $3.8 million in gross profit and gross margins of 50.2% during the third quarter of 2008. The decrease in cost of goods sold was a result of lower raw material prices from the Sichuan province as production fully resumed after the 2008 earthquake. Gross profits surged by 216.3% for the three months ended September 30, 2009.

Operating expenses for the three months ended September 30, 2009 were approximately $7.9 million, an increase of 151.3% compared to the same period in 2008. The increase was primarily due to increase in promotional and advertising expenditures of $2.4 million in support of the Biostar's product and brand awareness marketing strategy. Biostar also expensed $0.5 million on research and development in the quarter as part of new product development strategy.

Operating income for the third quarter of 2009 totaled approximately $4.1 million, a 524.9% increase from the $0.7 million reported for the third quarter of 2008. Operating margins were 26.4% and 8.7% for the third quarter of 2009 and 2008, respectively.

Net income was approximately $3.1 million in the third quarter of 2009, a 459.1% increase compared to $0.6 million for the third quarter of 2008. The company maintains an effective tax rate of 24.0% at September 30, 2009. Diluted earnings per share were $0.13 for the third quarter of 2009 compared to $0.02 for the third quarter of 2008, based upon 23.7 million and 23.2 million shares.

"We are very pleased to report another quarter of strong revenue growth and improved profitability. The success of our marketing strategy, strong sales of our Hepatitis B product, the Xin Aoxing Capsule, and expansion of rural supply network enabled us to achieve record breaking sales and earnings for the quarter," commented Ronghua Wang, Chairman and Chief Executive Officer of Biostar. "The Chinese government's stimulus plan includes $126 billion in health care reform and support of the New Rural Cooperative Medical System, which is providing the means to improve health care services for all Chinese citizens. This provides a solid foundation for sustained growth of the Chinese pharmaceutical industry and will benefit our company. We are confident that our strong product portfolio, proven sales team, experienced and committed management team will enable us to continue to execute our growth plan and capitalize on these long-term, secular growth opportunities."

Nine Month Results

For the nine months ended September 30, 2009, revenues increased approximately 52.5% to $36.2 million compared to $23.8 million in the same period of 2008. Gross profits were $26.5 million for the first nine months of 2009, representing an increase of 98.5% from the first nine months of 2008. Gross margins increased 30% to 73.1% for the first nine months of 2009 compared to 56.2% for the same period in 2008.

Income from operations increased 147.9% year over year to $11.9 million for the first nine months of 2009. Operating margins were 32.8% and 20.2% for the first nine month of 2009 and 2008, respectively.

Net income was $8.8 million for the nine months ended September 30, 2009, an increase of 112.9% from the same period in 2008. Diluted earnings per share were $0.37 for the first nine months of 2009 compared to $0.18 for the first nine months of 2008, based up on 23.7 million and 23.2 million shares respectively.

Balance Sheet and Cash Flow

Cash and cash equivalents totaled $2.4 million on September 30, 2009 compared to $0.8 million on December 31, 2008. Accounts receivable balance was approximately $17.9 million on September 30, 2009 versus approximately $11.7 million on December 31, 2008. Days sales outstanding (DSO) were at 104 days. The Company had a current ratio of 5.9 to 1 and stockholders' equity of $32.5 million, with total assets of $37.1 million versus total liabilities of $4.5 million on September 30, 2009.

For the first nine months of 2009, the Company generated $2.9 million in cash from operations versus reported $0.5 million used in operations for the same period in 2008.

Business Developments

On November 6, 2009, Biostar announced the closing of a private placement financing of approximately $3.6 million with certain accredited investors. The "Make Good" target associated with this financing is measured by income from operations of $15.9 million for 2009, and $21.1 million for 2010. The Company will use the net proceeds for the completion of the Company's new raw materials processing facility.

On November 3, the Company announced it has expanded its rural supply network to 3,512 sales outlets in rural areas of 6 provinces. The Company will continue working toward its goal of covering 5,000 sales outlets by the end of 2009 and 10,000 sales outlets by 2011. The Company expects the rural supply network to contribute more than $10.0 million in annual revenues in 2010 with average annual revenue generated from each sales outlet of $2,000.00.

On October 7, Biostar announced the Chinese Military Drug Administration granted clearance to begin clinical trials on Biostar's new drug, Zushima Analgesic Aerosol Spray. The Company anticipates formal product approval by the Chinese Military Drug Administration in the second quarter of 2010. The product is expected to contribute at least $2.0 million to revenues in 2010.

On October 2, 2009 Biostar Pharmaceuticals reported it received a patent from China's State Intellectual Property Bureau for its Aoxing Ganbao, which is a complementary medicine for its flagship Xin Aoxing Capsule in treating Hepatitis B. Aoxing Ganbao is a TCM product applied topically and effective to nourish the liver and reduce inflammation without side effects. The patent will prevent its competitors from producing similar products for 20 years.

"We are making progress on all aspects of our business including the rural supply network, raw material processing facility, and new products. We will continue to expand Xin Aoxing Capsule product's market and we expect further penetration of the new markets we just entered. We will remain focused on these initiatives which will contribute to our long-term growth profitability. We are committed to creating value for our shareholders and will continue to implement and execute a growth plan which will enable us to accomplish this goal," concluded Mr. Wang.

Conference Call

The Company will host a conference call to discuss the 2009 third quarter financial results on Thursday, November 12, 2009 at 9:30 a.m. ET. Interested participants should call +1-888-549-7704 within the United States, or US +1-480-629-9857 if calling internationally. The conference ID is 4182017. It is advisable to dial in approximately 5-10 minutes prior to 9:30 a.m. ET. This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at or at the following link: . To access the web cast, you will need to have the Windows Media Player on your desktop. For the free download of the Media Player please visit: .

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and thirteen nutrients. The Company has adopted international standards and is in the process of applying for two patents.

Safe Harbor

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our S-1 dated June 27, 2008, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, our 10-K for the year ended December 31, 2008, and other recent filings. These filings are available at . We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

                          BIOSTAR PHARMACEUTICALS, INC.
                           CONSOLIDATED BALANCE SHEETS

                                              September 30,     December 31,
                                                   2009             2008
    Current Assets
    Cash and cash equivalents                    $2,448,667         $758,316
    Accounts receivable                          17,851,863       11,700,841
    Inventories                                     706,624          315,745
    Prepaid expenses and other receivables        5,617,468        2,926,505
    Total Current Assets                         26,624,622       15,701,407

    Property and equipment, net                   3,301,541        5,930,467

    Intangible assets, net                        7,147,701        7,365,765

    Total Assets                                $37,073,864      $28,997,639


    Current Liabilities
    Accounts payable and accrued expenses        $2,446,257       $2,191,976
    Customer and other deposits                     105,066        2,592,250
    Value-added tax payable                       1,000,837          527,103
    Income tax payable                              988,791          413,205
    Total Current Liabilities                     4,540,951        5,724,534


    Stockholders' Equity
    Series A, convertible preferred stock,
     $0.001 par value, 5,000,000 shares
      None issued and outstanding                        --               --
    Undesignated preferred stock, $.001 par
     value, 5,000,000 shares authorized,
      None issued and outstanding                        --               --
    Common stock, $.001 par value, 100,000,000
     shares authorized, 23,240,899 shares
     issued and outstanding at September 30,
     2009 and December 31, 2008                      23,241           23,241
    Additional paid-in capital                   10,430,168       10,430,168
    Statutory reserves                            2,487,480        1,585,383
    Retained earnings                            18,904,913       10,996,655
    Accumulated other comprehensive income          687,111          237,658
    Total Stockholders' Equity                   32,532,913       23,273,105

    Total Liabilities and Stockholders' Equity  $37,073,864      $28,997,639

                          BIOSTAR PHARMACEUTICALS, INC.

                          Three Months Ended           Nine Months Ended
                            September 30,                September 30,
                          2009          2008           2009          2008

    Sales, net        $15,556,345    $7,541,534    $36,249,051   $23,772,567

    Cost of sales       3,585,143     3,756,445      9,753,704    10,423,651

    Gross profit       11,971,202     3,785,089     26,495,347    13,348,916

    Selling, general
     and administrative
     expenses           7,857,258     3,126,704     14,608,550     8,553,999

    Income from
     operations         4,113,944       658,385     11,886,797     4,794,917

    Other Income
    Interest income           488           841            981         2,362
    Interest expense           --       (10,463)            --       (39,945)
    Loss on disposal
     of building               --            --       (248,730)           --
    Foreign exchange
     loss                      --            --            (10)           --
    Total other Income
     (Expense)                488        (9,622)      (247,759)      (37,583)

    Income before
     income taxes       4,114,432       648,763     11,639,038     4,757,334

    Provision for
     income taxes         988,286        89,580      2,828,683       619,055

    Net income         $3,126,146      $559,183     $8,810,355    $4,138,279

    Net income per
     common share
    Basic                   $0.13         $0.03          $0.38         $0.19
    Diluted                 $0.13         $0.02          $0.37         $0.18

    Weighted average
     common shares
    Basic              23,240,899    22,152,311     23,240,899    22,152,311
    Diluted            23,720,233    23,240,899     23,720,233    23,240,899

                          BIOSTAR PHARMACEUTICALS, INC.

                                                   Nine Months Ended
                                                      September 30,
SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
2. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
6. BioMarin Acquires Huxley Pharmaceuticals, Inc.
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
8. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
9. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
10. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
Post Your Comments:
(Date:10/9/2015)... REDWOOD CITY, Calif. , Oct. 9, 2015 ... a presentation will be made at the annual European Society ... th to October 14 th , 2015 at the ...  The annual EuSEM is the largest meeting of emergency medicine ... and 90 countries represented. Data from the previously ...
(Date:10/9/2015)... Oct. 9, 2015 Ansun BioPharma announced a ... of America ) regarding the compassionate use of DAS181 ... a respirator who was co-infected with influenza and parainfluenza ... of therapy, O 2 requirement was reduced and ... able to go off the respirator on day 5. ...
(Date:10/9/2015)... , Schweiz, October 9, 2015 Der ... Dr.   Yutaka Kondo und Dr.   Junko Takita ...   2015 " geht an Dr.   Yutaka ... Der " JCA-Mauvernay Award   2015 ... Dr.   Junko Takita    ™ , das ...
Breaking Medicine Technology:
... Nov. 9, 2011 BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX® in the U.S. ... Tom Wegman, will present at the upcoming Lazard Capital ... Wednesday, November 16, 2011 in New York, NY.   ...
... 9, 2011 NeuroDerm , Ltd. ... and pharmacokinetic trial of ND0611, administered as an adjunct ... or Stalevo ® , in patients with advanced Parkinson,s ... sub-cutaneously via a dermal patch to increase the bioavailability ...
Cached Medicine Technology:
(Date:10/10/2015)... York, NY (PRWEB) , ... October 10, 2015 , ... ... some alarming numbers on the growth of cybercrime costs for US companies. The New ... on Tuesday, October 6th. With averages showing increases hovering around 20% among the companies ...
(Date:10/10/2015)... , ... October 10, 2015 , ... Isabel Healthcare will ... , On the heels of the release of the Institute of Medicine’s latest report ... their integration with Cerner solutions that assist healthcare providers and consumers to potentially reduce ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic ... for Graduate Medical Education J. Michael Finley, DO, as the recipient of the ... for his impact on graduate medical education opportunities for osteopathic residents, and his ...
(Date:10/9/2015)... ... 2015 , ... A new health tool that helps identify if a sore ... ) – just in time for the cold and flu season, which the ... many in the U.S., the real start of cold/flu season is the start of ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington ... orthodontic system that uses clear, plastic aligners. This alternative to braces has become ... which allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, ...
Breaking Medicine News(10 mins):
... serious problem that can often be fatal. Methadone has ... addicts. However, the major concern in treating heroin addicts ... is one reason methadone therapy is usually only given ... that an alternative drug therapy combined with psychosocial treatment ...
... researchers are currently testing the safety of hypothermia ... injury. Hypothermia treatment has been shown to be ... but its effectiveness in treating children with traumatic ... decreases inflammation, excitotoxicity (excessive neurotransmitters released with injury ...
... of skin cancer and it has been shown through previous ... sunlight, whose UV rays cause damage to DNA that triggers ... are more prone than others to melanoma. Researchers have now ... people with melanoma that those with fair skin// have lowered ...
... Affective Disorder(SAD) is not all that well understood, but ... sunlight in the winter months. Winter depression involves suffering ... days get longer and nights get shorter. Other SAD ... sleeping for longer than usual. Researchers have now found ...
... hospital in Kolkatta, India recently received a patient, a two-month-old ... suffering from a rare disease caused due to a deficiency ... of 10 million children. Doctors said that the baby was ... On detection the baby, a boy child, was found to ...
... time to its ultraviolet rays, has always been said to be ... shown that even moderate sun exposure can result in moles that ... to sun has been shown as the main risk factor for ... rarest type of skin cancer, is much weaker. It has however, ...
Cached Medicine News:
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: